Pediatric-Onset Multiple Sclerosis in Multiple Autoimmune Syndrome: Reporting This Rare Entity in 2 Pediatric Patients.

J Child NeurolFeb 6, 2026 (epub)

Evangelia Bechlivani, Konstantinos Notas, Efterpi Pavlidou et al.

✦ AI-curated · Sources linked

Case in brief

The report describes two children with pediatric-onset multiple sclerosis (POMS) who also met criteria for multiple autoimmune syndrome (MAS), defined as three or more autoimmune disorders in one person. One had type 1 diabetes and autoimmune thyroiditis; the other had rheumatoid arthritis and autoimmune thyroiditis. Both were positive for HLA-DRB1*15:01 and Epstein-Barr virus IgG and had severe vitamin D deficiency. The authors present POMS in these cases as part of a broader autoimmune diathesis and emphasize early recognition, screening, and multidisciplinary management.

What made this case unusual

The notable feature is the coexistence of POMS with MAS in children, alongside shared HLA-DRB1*15:01 positivity, EBV IgG seropositivity, and severe vitamin D deficiency in both patients.

Diagnostic / clinical pearl

In a child with POMS, consider whether additional autoimmune disorders meet criteria for MAS; the report supports attention to systemic autoimmune disease and multidisciplinary assessment.

Why it matters

The authors call for multicenter and registry-based studies to clarify how often MAS occurs in pediatric MS and its mechanisms and prognostic implications.

Source

Published in J Child Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.